More data need to be attained on the response of dactylitis or enthesitis to different therapies when compared with arthritis and skin disease.

How does dactylitis or enthesitis affect physical function, health-related quality of life, social participation or cardiovascular risk?

To what extent does their inclusion in composite measures increase or decrease validity and sensitivity to change?

More data need to be attained on the response of psoriasis to different therapies when compared with arthritis and other musculoskeletal symptoms.

How does skin involvement affect physical function or cardiovascular risk?

To what extent does its inclusion in composite measure increase or decrease validity and sensitivity to change?

To what extent do skin changes affect quality of life, work participation and social inclusion beyond the respective effects of arthritis and other musculoskeletal manifestations?

Is imaging useful for follow-up in axial SpA and PsA?

Should imaging remission be a treatment target in axial SpA and PsA?

What is the impact of functioning/disability in composite measures developed for PsA?

Strategic trials in axial SpA and at least one additional strategic trial in PsA.

How can response be maintained?

Can the dose of the therapy employed be reduced or the interval of applications be expanded and outcome maintained?

Is care of axial SpA, peripheral SpA or PsA by a specialist (such as a rheumatologist) advantageous for outcomes when compared with care by a non-specialist?

Is outcome different when patients are informed in a structured way when compared with more general means of information?

Nomenclature should be harmonised—remission vs inactive disease; minimal disease activity vs low disease activity, etc.

Does achievement of the treatment target result into prevention or retardation of structural damage development in the spine/peripheral joints in SpA?

We need better biomarkers of disease activity than CRP for both axial SpA and PsA.